Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Ruth Plummer

Newcastle AuthorsTitleYearFull text
Dr Nicola Cresti
Professor Ruth Plummer
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine2019
Professor Ruth Plummer
Dr Alastair Greystoke
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours2019
Professor Ruth Plummer
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial2019
Dr Simon Findlay
Dr Jason Gill
Professor Ruth Plummer
Carol De Santis
Dr Chris Plummer
et al.
Chronic cardiovascular toxicity in the older oncology patient population2019
Professor Ruth Plummer
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial2019
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Dr Marina Danilenko
Elaine Stamp
Dr Deborah Stocken
Monique Zangarini
Amy Cranston
et al.
Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib2018
Professor Ruth Plummer
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers2017
Professor Ruth Plummer
Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma2017
Dr Alastair Greystoke
Dr Noor MD Haris
Professor Ruth Plummer
SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting2017
1234567891011121314151617